









Markets
/
Stocks
/
nasdaq-adpt
/

Adaptive Biotechnologies Corp

ADPT

13.220USD

+0.090+0.69%

Close 09/26, 16:00（ET）Quotes delayed by 15 min

2.01BMarket Cap

LossP/E TTM



Adaptive Biotechnologies Corp

13.220

+0.090+0.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-26

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

49 / 505

Overall Ranking

137 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.000

Target Price

+5.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Undervalued

The company’s latest PE is -16.26, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 148.68M shares, decreasing 3.06% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 29.99M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-26

The company's current financial score is 7.39, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 58.88M, representing a year-over-year increase of 36.33%, while its net profit experienced a year-over-year increase of 44.58%.

Score

Industry at a Glance

Previous score

7.39

Change



Financials

5.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.60

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.37

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-26

The company’s current valuation score is 6.95, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -16.26, which is -90.32% below the recent high of -1.57 and -5.45% above the recent low of -17.14.

Score

Industry at a Glance

Previous score

4.00

Change

2.95

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 49/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-26

The company’s current earnings forecast score is 8.29, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Adaptive Biotechnologies Corp is 15.00, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.000

Target Price

+5.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Adaptive Biotechnologies Corp

ADPT

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

argenx SE

ARGX

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-26

The company’s current price momentum score is 6.94, which is higher than the Biotechnology & Medical Research industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 14.35 and the support level at 12.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.91

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Neutral

RSI(14)

52.973

Neutral

STOCH(KDJ)(9,3,3)

37.180

Sell

ATR(14)

0.783

High Vlolatility

CCI(14)

-11.938

Neutral

Williams %R

58.782

Sell

TRIX(12,20)

0.309

Sell

StochRSI(14)

29.977

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

13.408

Sell

MA10

13.298

Sell

MA20

13.070

Buy

MA50

12.274

Buy

MA100

11.275

Buy

MA200

9.385

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-26

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 97.64%, representing a quarter-over-quarter decrease of 5.11%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 29.99M shares, representing 19.70% of shares outstanding, with 2.96% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Viking Global Investors LP

Star Investors

29.99M

The Vanguard Group, Inc.

Star Investors

11.12M

+4.01%

BlackRock Institutional Trust Company, N.A.

9.79M

-0.20%

Rubric Capital Management LP

13.12M

-10.15%

Amova Asset Management Co., Ltd.

6.09M

-10.94%

ARK Investment Management LLC

Star Investors

4.40M

-27.51%

Braidwell LP

4.80M

Geode Capital Management, L.L.C.

2.78M

+3.59%

State Street Global Advisors (US)

2.69M

-1.48%

Aristotle Atlantic Partners, LLC

2.94M

+1.89%

Risk Assessment

Currency: USD Updated: 2025-09-26

The company’s current risk assessment score is 5.38, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 2.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.